Background: Surveillance, Epidemiology, and End Results Cancer Registries (SEER) began collecting human papillomavirus (HPV) status for upper aerodigestive tract cancers in 2010. However, classification of p16-testing was not included in the Collaborative Stage coding guidelines, potentially leading to inconsistent coding.
| I NT ROD UCTI ON
Human papillomavirus (HPV) infections are the most common sexually transmitted infections in the United States. It is estimated that >90% of sexually active men and 80% of sexually active women will be infected with HPV in their lifetimes. 1 Approximately half of these are infected with a highrisk HPV-type, which is known to be a major risk factor for developing cancer. 1 Incidence of oropharyngeal squamous cell carcinoma (SCC) has been rising for the past several years, with 70% of patients testing positive for HPV-DNA. 2 Oropharyngeal cancer accounts for 78% of all HPVassociated cancers among men and 12% among women. 2 In 2008, the National Comprehensive Cancer Network first suggested that HPV-testing should be performed for patients with an oropharyngeal or occult primary, because patients with HPV-positive oropharyngeal SCC have been shown to have a substantially higher 5-year survival (75%) compared with HPV-negative patients (14%). 3, 4 The only HPV tests recommended at that time were polymerase chain reaction and in situ hybridization (ISH). Beginning with patients diagnosed in 2010, the Surveillance, Epidemiology, and End Results (SEER) registries have collected HPV testing as a site-specific factor (SSF-10) for upper aerodigestive tract cancers (oropharynx, oral cavity, nasopharynx, hypopharynx, and larynx). In 2013, the College of American Pathologists recommended that HPV testing be added to their standard pathologic evaluation of oropharyngeal SCC and, in 2016, the College of American Pathologists convened a panel to develop a clinical practice guideline for HPV testing for patients with oropharyngeal cancer. 5 HPV testing is expected to be routinely performed but no standard method of testing has been specified, so test type remains at the discretion of the laboratories. 6 These tests have a variety of targets, including HPV-DNA, HPV-RNA, cellular proteins, and HPVspecific serum antibodies. For many reasons, it has become common to test for p16, a surrogate marker of HPV activity, via immunohistochemistry (IHC). The presence of p16 is highly correlated with HPV-driven SCC. [7] [8] [9] [10] The latest National Comprehensive Cancer Network guidelines (2016) now suggest HPV testing via polymerase chain reaction, ISH, or p16 IHC.
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The evolving use of p16 as a surrogate HPV test has potentially led to some inconsistencies in the interpretation of the Collaborative Stage guidelines for the HPV variable collected by cancer registrars since 2010. Collaborative Stage guidelines for SSF-10 mention that HPV results can be found in IHC staining in pathology reports and that p16 is the standard method of testing. 12, 13 However, guidance from the American Joint Committee on Cancer (AJCC) stated that patients tested with only the p16 IHC marker should be coded as 999 (unknown). 13 Furthermore, p16-testing is not specifically mentioned in any of the code descriptions for SSF-10. The purpose of this study was to review HPV test status for all patients with oropharyngeal SCC to determine the following: (1) accuracy of SSF-10; (2) types of HPV testing being performed in Iowa; (3) impact of excluding p16 from the definition of HPV testing; and (4) patient, tumor, and facility characteristics associated with HPV testing.
| M ATE RI ALS AN D ME THO DS

| Data source
A secondary data analysis of Iowa Cancer Registry data, extracted from their SEER Data Management System (SEER*DMS), was conducted. The Iowa Cancer Registry is 1 of the original 9, of the now 18, population-based cancer registries that are a part of the National Cancer Institute's SEER program. Since 1973, the Iowa Cancer Registry has been capturing cancer diagnoses among Iowans. Together, all 18 registries provide cancer surveillance information for about 28% of the US population. The types of information captured by these registries include patient demographics, tumor characteristics, specific cancer markers, stage at diagnosis, first course of treatment, and patient survival. 14 This information is captured from hospitals, pathology laboratories, radiology facilities, physician offices, and other facilities. Records for all eligible patients were manually reviewed to determine if HPV testing was completed, and, if so, which pathology tests were performed. Pathology reports were sought for each case when the SEER*DMS text was unclear regarding HPV testing. If a pathology report was not available, additional medical record information was sought from the hospital that provided the greatest amount of care. This study was granted human subject exemption status by the University of Iowa Institutional Review Board.
| Study population
We initially identified 1064 patients with invasive or in situ upper aerodigestive tract cancers who were Iowa residents and diagnosed between 2010 and 2014. The International Classification of Diseases for Oncology-3 topographies included those listed in the Collaborative Stage schema for HPV status that SEER registries were instructed to follow, which includes: tongue base C01.9, C02.4; soft palate C05.1 to C05.2; oropharynx C09.0 to C09.1, C09.8 to C09.9, C10.0, C10.2 to C10.4, C10.8 to C10.9; pharyngeal tonsil C11.1; nasopharynx C11.0 to C11.3, C11.8 to C11.9; hypopharynx C12.9, C13.0 to C13.2, and C13.8 to C13.9; and pharynx other C14.0 to C14.2, and C14.8. This dataset was then limited to patients with oropharyngeal SCC (cancer of the soft palate, tongue base, and oropharynx, not otherwise specified [NOS]; International Classification of Diseases for Oncology-3 histologies: 8032, 8050-052, 8070-8076, 8078, 8082-8084, and 8801). Patients were excluded if they were not in the SEER*DMS, we were unable to discern HPV test type or results, or did not have oropharyngeal cancer or a histology of squamous cell carcinoma (N 5 240).
| Modified guidelines used in recoding human papillomavirus status
Stage SSF-10 definitions. 15 If p16 testing (IHC) was the only test performed, the patients with p16-positive cancers were coded as "070: HPV positive -types not stated (NOS)," or if it was stated as high risk, then the case was coded as "060: HPV positive-high risk types, NOS." The p16-negative patients were coded as "000: negative." If both p16 testing and HPV-DNA testing were performed, results were classified according to the HPV-DNA results. 
| Study variables
| Statistical analysis
Differences in patient, tumor, treatment, and facility characteristics were compared between patients who received HPV testing and those who did not using chi-square tests. Logistic regression was used to determine characteristics associated with receipt of HPV testing. All variables listed above were considered for inclusion into the model. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and SEER*Stat version 8.3.4. 16 
| RES U LTS
There were 824 patients with oropharyngeal SCCs who met inclusion criteria. Based on Collaborative Stage guidelines, 45% (n 5 372) were coded as having had HPV testing (codes 000-070 and 997). After applying our modified guidelines, 55% (n 5 450) had HPV testing (Table  T1  1 ). Applying our modified guidelines among all those tested, 73% (n 5 328) tested positive for HPV and/or p16. The majority received p16 testing only (56%), followed by p16 and HPV-DNA testing (23%) and HPV-DNA testing only (20%). Those who had p16 testing only had a higher rate of HPV-positive results (80%) compared with those who had HPV-DNA testing only (62%) or both (65%; P < .0001). Among those who had both p16 and HPV-DNA testing, 65% (n 5 68) were positive for both p16 and HPV, and 25% (n 5 26) had discordant results (Table 1) . Discordant results refer to patients who were either negative for HPV but positive for p16 or positive for HPV but negative for p16.
Applying our modified guidelines, 44% of patients (n 5 359) were recoded to a different SSF-10 value than initially documented using Collaborative Stage guidelines (Table  T2  2 upper). Of the recoded patients, 52% (n 5 187) were originally coded as "030: HPV positive-type 16 only" and 70% (n 5 250) were recoded as "060: HPV positive-high risk types, NOS" or "070: HPV positive-NOS." Of the originally coded "030: HPV positive-type 16 only" patients, 89% (n 5 187) were recoded; 94% of these (n 5 175) were recoded as 060 or 070. After recoding, it was found that 18% of patients (n 5 83) originally coded as "998: test not done" or "999: unknown" had some form of HPV testing performed. Of these patients, 83% (n 5 69) received only p16 testing or a combination of p16 and HPV-DNA testing. When collapsing all of the SSF-10 values into the following 3 categories: HPV-positive, HPV-negative, and not tested, and then comparing the categories based on Collaborative Stage guidelines versus our modified guidelines, the initial coding based on the Collaborative Stage guidelines accurately identified 81% of patients with HPV-positive cancers, and 68% of HPVnegative patients (Table 2 lower) .
Recoding according to the AJCC guidance that excluded p16 as an HPV test (ie, coding p16 testing only as "999: unknown") resulted in 69% of patients (n 5 144) who were originally coded as "030: HPV positive-type 16 only" and 48% of patients (n 5 42) who were originally coded as "000: negative" to be reclassified as "999: unknown" (Table  T3  3 upper). Overall, based on this recoding according to the AJCC guidance, 55% of patients (n 5 203) who were originally tested for "HPV" were reclassified as "999: unknown" (Table 3 lower). This led to 76% (n 5 628) of the 824 cases being classified as unknown.
We examined characteristics associated with HPV testing using our modified guidelines. Table  T4 4 displays the frequencies, percentages, and P values corresponding to chi-square tests for patient, tumor, and treatment characteristics by HPV testing status. Odds ratios and 95% confidence intervals are also displayed from a logistic model in which the dependent variable was HPV testing and the independent variables included all variables listed in Table 4 , except for the test type and test results (N 5 799 due to 25 patients missing values for facility characteristics). Univariate analysis demonstrated that all variables, except race/ethnicity and sex, were significantly associated with HPV testing. The HPV testing rates varied the most by age (65% for those <50 years vs 41% 751 years), diagnosis year (29% in 2010 vs 75% in 2014), and site (60% oropharynx vs 24% soft palate). The following variables were significantly associated with HPV testing in the logistic model (P < .05): later diagnosis year, cancer of the oropharynx, poorly differentiated grade (vs well differentiated), receiving surgery, and being treated at a hospital with 5001 beds.
When comparing the 26 patients with discordant results to the study population who had concordant p16 and HPV results (n 5 78), no significant differences in patient, tumor, or facility characteristics were detected (data not shown). However, there were differences in facility characteristics when looking at whether a patient received only p16 testing, only HPV-DNA testing, or received both tests. Patients who received only p16 testing more frequently went to Academic Comprehensive designated hospitals and major teaching hospitals (51% and 55%, respectively), whereas those who received HPV-DNA testing only or both tests more frequently went to Comprehensive Community and Veterans' Administration designated hospitals (56% and 63%, respectively) and minor teaching hospitals (38% and 56%, respectively; data not shown).
Although our analysis focused solely on Iowa patients with cancer, we wanted to assess how the Iowa registry compared to the other SEER registries to determine the variation in HPV coding across registries. Figure  F1  1 depicts the HPV testing rates for patients with oropharyngeal SCC among the SEER-18 registries (excluding Alaska due to their small number of patients) diagnosed from 2010 to 2014. The HPV testing rates varied from 33% to 57% (Seattle; Connecticut). Although Iowa originally had a testing rate of 45%, after recoding, its rates exceeded those of other registries (55%), except Connecticut and Utah (57% and 55%, respectively). Compared with other code values, "030: HPV positive-type 16 only" was the most common code for those with positive results. After recoding in Iowa, the "030: HPV positive-type 16 only" rate decreased from 26% to 4% among those with positive results, whereas the NOS values ("060: HPV positive-high risk types, NOS" and "070: HPV positive-NOS") rose from 7% to 35%.
| DI S CU S S IO N
Review of Iowa patients with oropharyngeal SCC revealed issues with consistency and accuracy of the HPV testing SSF-10 variable. Consistent application of our modified guidelines, which included p16 testing, led to a substantial increase in the reported testing rate from 45% to 55% during Abbreviations: HPV, human papillomavirus; NOS, not otherwise specified; SSF, site-specific factor.
Numbers in dark gray represent HPV status values that did not change according to our modified guidelines.
Numbers in white and light gray represent HPV status values that did change according to our modified guidelines. Blanks indicate there were no patients with that combination of SSF-10 codes. Ellipses indicate there were no patients with that SSF-10 code. 2010-2014. It also led to a large shift in the distribution of values from "030: HPV positive-type 16 only" to HPV NOS, "060: HPV positive-high risk types, NOS" or "070: HPV positive-NOS." likely because registrars were erroneously equating p16-positivity with HPV-type 16. Among those assessed for HPV status, over half of Iowa patients received only p16 testing and an additional 23% received p16 testing first, followed by an HPV-DNA test. Given that p16 is the predominant test to assess HPV status in Iowa, completely excluding it as an HPV test would cause currently reported testing rates in Iowa to decline from 45% to 21%. Based on our findings, it is imperative that coding options and guidelines for SSF-10 be updated to improve the accuracy, consistency, and usefulness of this variable. This study has identified an inconsistency in the coding of HPV status in Iowa for patients with oropharyngeal tumors, under the Collaborative Stage schema used for national cancer databases including SEER and the National Cancer Database. Although we are not aware that a similar inconsistency has previously been reported in data collected in other registries, we presume that it is most likely that other cancer registries would find similar results. It is difficult to estimate the effect this inconsistency in coding has on the data currently available to the public from these national databases, and the bias this introduces in observational studies. In Iowa, 18% of patients with HPV-associated tumors were not originally identified as such. This omission certainly affects epidemiologic estimates of the incidence of p16-positive oropharyngeal cancers, and decreases the available sample size of patients for inclusion in studies of HPV-associated oropharyngeal cancers. It would also affect studies that make comparisons between the HPVpositive subset and the unknown-status subset of patients. Separately and similarly, the coding of discordant p16-positive HPV-negative patients into "000: negative" also creates a systematic bias in studies that examine outcomes for HPV-negative patients. Although our findings do not change how clinicians interpret patient records, clinicians should be aware of this issue when interpreting literature derived from cancer registry data.
Published studies utilizing SSF-10 to stratify outcomes demonstrate an unawareness of the inconsistency in registrar coding of p16 as a surrogate marker for HPV. For instance, a study based on National Cancer Database data from 2009-2011 comparing HPV-negative to HPV-positive oropharyngeal cancers states that SSF-10 defines patients with HPVpositive disease based on ISH tests for HPV-16 or HPV-18, and/or positive p16 staining by IHC. 17 The definition of SSF-10 in the Collaborative Stage schema does not mention p16 staining by IHC. These data in this present study suggest that the assumption by Amini et al 17 regarding p16 testing being included is partially inaccurate, although whether this affects the study's analysis and conclusions is difficult to judge.
For maximum clarity and completeness, the creation of a new and separate SSF for p16 (SSF-11 "p16 status") would The Iowa data are as presented in Table 2A , whereas the remaining SEER registries' HPV SSF-10 values were derived from SEER*Stat. HR, high risk; NOS, not otherwise specified
be ideal. This variable could easily capture if an IHC test for p16 was negative (000), positive (010), or not done/unknown (998 and 999). This would be a clean and simple way to capture the p16 status of patients and subsequent code values would not have to be added to current SSFs. Given the major changes in the AJCC eighth edition staging manual, in which a separate staging algorithm has been developed for HPVassociated oropharyngeal cancer based on p16 status, p16 status will be a critical prognostic for cancer registries to collect. 18 The provision of more education around p16 in the guidelines, as well as clarification that p16 is not testing for HPV-type 16, would likely be beneficial in assisting registrars to code this variable accurately and consistently. The SSF-10 code distribution among the registries displayed in Figure 1 suggests that staff in other registries were also erroneously classifying p16-positive as HPV-type 16-positive, as the 030 code was the most commonly recorded among those with positive results, whereas our recoding in Iowa suggests that 030 should be far less common than the 060 and 070 codes.
Although a new SSF for p16 and more comprehensive guidelines and education focused on p16 and HPV status would improve the quality of data for upper aerodigestive tract cases collected by the registries in the future, there still are potential uses of the HPV data already collected (diagnosis years 2010-2014) despite the aforementioned coding issues. The overwhelming majority (81%) of HPV-positive cases were captured by the original registry coding based on Collaborative Stage guidelines. Thus, certain research questions could be potentially addressed using the data for those cases already collected based on Collaborative Stage guidelines (eg, epidemiology of oropharyngeal SCC within the HPV-positive population irrespective of HPV type). However, research questions focused on evaluating patients based on presence or absence of HPV testing or on specific types of HPV (eg, HPV-type 16) could be problematic among cases diagnosed in 2010-2014. This study has limitations that should be considered when interpreting results. For analytic purposes, patients who received both p16 and HPV-DNA testing were classified according to their HPV-DNA results and 26 of these patients had discordant results. As previously mentioned, p16 results may actually be a better indicator of prognosis. Further study of these patients could lead to refinements in survival estimates obtained from SEER data.
Another limitation involved the inconsistencies in the structure of, and language used in, pathology reports from many different institutions. Due to the unstructured nature of some of the reports, it is possible that classification of test types were incorrect in some patients. Two members of the study team are pathologists and assisted with interpretation of terminology used in the reports to ensure maximum accuracy in classifying test types. Finally, the models developed in this study were based only on patients residing in Iowa at the time of diagnosis, so results may not generalize to patients in other areas.
This study also has important strengths. The HPVtesting rates in Iowa across patient, tumor, treatment, and facility characteristics were assessed using data from a large population-based registry. This is one of the first studies to identify and report the type of HPV testing being performed, which showed large inconsistencies in coding. It is also one of the first studies providing a population-based estimate of HPV testing among patients with oropharyngeal cancer treated in a wide variety of hospital sizes and locations.
The nature of oropharyngeal cancer across the population has changed over the past 2 decades due to the effect of HPV. As such, there is an ongoing need for accurate epidemiologic data to inform clinical practice and investigation. Our data show that capturing p16 as a synonymous marker for HPV testing is required for optimal accuracy. Given the large difference in survival outcomes between HPV-positive and HPV-negative oropharyngeal cancer, accurate registry assessment of HPV status is required to assess changes in survival over time. Such information is also important to understand treatment decisions: for example, the ongoing Eastern Cooperative Oncology Group 3311 and NRG-HN002 trials of treatment of HPV-associated oropharyngeal cancer specify the use of p16 IHC for registration and not HPV-DNA testing. If HPV status is eventually used to steer patients down different treatment paths, it is imperative that it is captured correctly in cancer registries so that practice patterns and survival implications associated with these different treatment paths can be assessed over time in the population. Important distinctions about clinical findings and outcomes would go uncaptured without modification of the SSF-10 guidelines.
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